驱动基因阳性NSCLC中MTAP缺失的基因组特征与临床影响:中国大规模真实世界队列研究
该研究基于6492例中国NSCLC患者真实世界基因组数据,分析MTAP缺失的分布特征,并在173例驱动基因阳性初治患者中评估一线靶向治疗的生存结局。MTAP缺失见于10.4%总体人群,在EGFR突变、ALK融合及MET/ERBB2扩增肿瘤中富集,与CDKN2A共缺失率达92.3%。在驱动基因阳性患者中,MTAP缺失与较低缓解率及更短PFS和OS相关,尤其见于接受三代EGFR-TKI治疗的EGFR突变患者。
要点
- MTAP缺失见于10.4%中国NSCLC患者,在EGFR突变、ALK融合及MET/ERBB2扩增中富集。
- MTAP缺失与CDKN2A共缺失率92.3%,完全缺失占87.8%,外显子8部分缺失占10.6%。
- 驱动基因阳性患者中MTAP缺失与较差靶向治疗结局相关,双缺失预后最差。
核心结论
- MTAP缺失定义NSCLC中一个独特的分子亚群,并在接受靶向治疗的EGFR突变疾病中作为稳健的不良预后生物标志物。
- 研究结果支持将MTAP状态纳入风险分层,并探索联合PRMT5或MAT2A抑制的策略。
研究设计与样本
- 基于真实世界数据库分析6492例中国NSCLC患者的基因组图谱。
- 在173例驱动基因阳性初治患者中评估一线靶向治疗的生存结局。
主要发现
- MTAP缺失见于10.4%的总体队列,在晚期及携带EGFR突变、ALK融合、MET扩增和ERBB2扩增的肿瘤中富集。
- MTAP缺失肿瘤中CDKN2A共缺失高度普遍,达92.3%。
- 结构上MTAP缺失以完全缺失为主,占87.8%,其余主要为涉及外显子8的部分缺失,占10.6%。
- 二代测序与免疫组化检测MTAP缺失的一致性高达92.1%。
- 驱动基因阳性患者中,MTAP缺失与较低缓解率及更短的无进展生存期和总生存期相关,尤其见于接受三代EGFR-TKI治疗的EGFR突变患者。
临床怎么用
- 对驱动基因阳性NSCLC患者可考虑检测MTAP状态以辅助风险分层。
- EGFR突变患者接受三代EGFR-TKI治疗时,MTAP缺失提示预后较差,可考虑更密切监测。
- MTAP缺失可作为探索PRMT5或MAT2A抑制剂联合策略的潜在标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: MTAP loss is a frequent genomic event in NSCLC, yet its clinical and therapeutic implications in oncogene-driven disease remain incompletely understood. METHODS: We analyzed genomic profiles of 6492 Chinese patients with NSCLC from a real-world database and evaluated survival outcomes in 173 treatment-naïve, driver-positive patients receiving first-line targeted therapies. Associations of MTAP loss with clinicopathologic characteristics, co-mutations, and outcomes were assessed, with particular attention to its interplay with CDKN2A loss. RESULTS: MTAP loss was identified in 10.4% of the overall cohort and was enriched in advanced stage and tumors harboring oncogenic drivers, including EGFR mutations, ALK fusions, and amplifications of MET and ERBB2. Co-deletion with CDKN2A was highly prevalent in MTAP-loss tumors (92.3%). Structurally, MTAP loss was predominantly complete (87.8%), with the remaining cases mainly comprising partial losses involving exon 8 (10.6%). A high concordance (92.1%) was observed between next-generation sequencing and immunohistochemistry for the identification of MTAP loss. In driver-positive patients, MTAP loss was associated with a lower response rate and shorter progression-free survival and overall survival, especially in EGFR-mutant patients treated with third-generation EGFR-tyrosine kinase inhibitors. Combined MTAP/CDKN2A analysis revealed a prognostic gradient, with dual loss conferring the worst outcomes and remaining an independent predictor in multivariable models. CONCLUSIONS: MTAP loss defines a distinct molecular subset of NSCLC and serves as a robust adverse prognostic biomarker in EGFR-mutant disease treated with targeted therapies. These findings support integrating MTAP status into risk stratification and exploring combination strategies that incorporate PRMT5 or MAT2A inhibition.
引用
- Wei Q, Wang Y, Hou T, et al. Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights From a Large-Scale Real-World Chinese Cohort. J Thorac Oncol. 2026. PMID: 42409117. doi:10.1016/j.jtho.2026.104077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。